The latest news from academia, regulators
research labs and other things of interest
Posted: Oct 17, 2011
RUSNANO and NEARMEDIC PLUS to Create New Nanomedicine Production Facility
(Nanowerk News) RUSNANO and NEARMEDIC PLUS will establish a pharmaceutical factory to manufacture original nanomedicines from the polymer-drug family of medicines that is the object of rapid development today. Manufacturing, which will encompass the entire cycle of drug production, will follow GMP principles. The project has a total budget in excess of four billion rubles of which RUSNANO will co-invest 1.2 billion rubles. Manufacturing facilities will be in Obninsk, in Kaluga Oblast. Production of the nanomedicines is scheduled to begin in late 2013.
NEARMEDIC's pharmaceuticals production will be based on KagocelŪ, a proprietary antiviral available over the counter and approved in Russia and CIS. Construction of the new GMP-tailored manufacturing facility will enable NEARMEDIC to remove production from rented facility and greatly expand production of Kagocel and further strengthen its domestic and international market positions.
Kagocel is a compound of an active plant-based gossypol molecule with a nanosized polymer. The joining of this small molecule to the high-molecular-weight polymer-carrier prevents absorption into the gastrointestinal tract with concomitant loss of the active ingredient into the organism. Kagocel prolongs the drug's pharmacological activity and avoids toxicity. Therein lies its uniqueness. Kagocel elicits the formation of alpha- beta and gamma-interferon in the human organism. The interferons have highly antiviral activity, effective in treatment and prevention of flu and other acute respiratory infections and in treatment of herpes infections (including recurrent genital herpes).
Since entering the market, Kagocel's sales have grown 13-fold, and they continue to rise at a faster pace that the rest of the antivirals market. The drug is one of the top ten medicines sold in this segment.
"The antiviral medicines segment is the most dynamically growing in the Russian pharmaceutical market," noted RUSNANO Managing Director Olga Shpichko. "The project will facilitate product expansion for this promising antiviral drug developed by Russian scientists".
RUSNANO was founded in March 2011 as an open joint stock company through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Anatoly Chubais is CEO and chairman of the Executive Board of RUSNANO.
Work to establish nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through reorganization of the Russian Corporation of Nanotechnologies.
NEARMEDIC PLUS, Ltd. is a multiprofile Russian medico-pharmaceutical biotechnology company that supplies modern diagnostic preparations (many proprietary), original medicines, and medical laboratory and diagnostic equipment to markets in Russia and countries of the CIS. The company has a network of outpatient clinics through which it directly provides medical services.